Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 13/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022610 | 1.00 | CTSS (0.36) | CTSSCYP19A1MAP3K12MEN1PDE7B | |
| SCHEMBL13888251 | 1.00 | CTSS (0.36) | CTSSCYP19A1MAP3K12MEN1PDE7B | |
| SCHEMBL2957527 | 0.85 | OPRD1 (0.37) | CTSSMEN1KCNH2TBXAS1 | |
| SCHEMBL13201154 | 0.83 | CYP19A1 (0.37) | CYP19A1MAP3K12MEN1CCR2KCNH2 | |
| SCHEMBL13221063 | 0.78 | CTSS (0.38) | CTSSMEN1KCNH2TBXAS1 | |
| SCHEMBL13201192 | 0.78 | CTSS (0.42) | CTSS | |
| SCHEMBL5027070 | 0.76 | CYP19A1 (0.38) | CYP19A1PDE7B | |
| SCHEMBL14048520 | 0.75 | CTSS (0.41) | CTSSKCNH2 | |
| SCHEMBL14446805 | 0.70 | CYP19A1 (0.41) | CYP19A1 | |
| SCHEMBL7176258 | 0.70 | CYP19A1 (0.42) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | CTSS 2119/4885CYP19A1 3129/4885MAP3K12 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.